^
Association details:
| Biomarker: | High 18-gene tumor inflammation signature score |
|---|---|
| Cancer: | Lung Non-Small Cell Squamous Cancer |
| Drug: | Tevimbra (tislelizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
WS06.05-RATIONALE-307: Updated Biomarker Analysis of Phase 3 Study of Tislelizumab Plus Chemo vs Chemo Alone For 1L Advanced Sq-NSCLC
Published date:
08/18/2021
Excerpt:
Significant treatment-specific differences in PFS were observed in patients with...an 18-gene tumor inflammation signature (TIS) (Interaction P-value: 0.001)....High TIS score was associated with significantly longer PFS in the tislelizumab plus chemotherapy group, but not in the chemotherapy alone group....This exploratory analysis of RATIONALE-307 is the first Phase 3 trial indicating a strong association between TIS score and clinical benefit of PD-1 blockade plus chemotherapy vs chemotherapy alone in sq-NSCLC.
Secondary therapy:
Chemotherapy
Trial ID:
